Cover Image
Market Research Report

Hemophilia Therapeutics Market by Type and Geography - Forecast and Analysis 2020-2024

Published by TechNavio (Infiniti Research Ltd.) Product code 925181
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
Hemophilia Therapeutics Market by Type and Geography - Forecast and Analysis 2020-2024
Published: February 4, 2020 Content info: 120 Pages
Description

Technavio has been monitoring the global hemophilia therapeutics market and it is poised to grow by USD 4.19 bn during 2020-2024, progressing at a CAGR of 6% during the forecast period. Our reports on global hemophilia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing number of initiatives to create awareness about hemophilia.

In addition, r&d of novel strategies to develop therapeutics is anticipated to boost the growth of the global hemophilia therapeutics market as well.

Market Segmentation

Technavioa's global hemophilia therapeutics market is segmented as below:

Type

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C

Geographic segmentation

  • North America
  • Europe
  • Asia
  • ROW

Key Trends for global hemophilia therapeutics market growth

This study identifies r&d of novel strategies to develop therapeutics as the prime reasons driving the global hemophilia therapeutics market growth during the next few years.

Prominent vendors in global hemophilia therapeutics market

We provide a detailed analysis of around 25 vendors operating in the global hemophilia therapeutics market, including some of the vendors such as Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd., Grifols SA, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi, Swedish Orphan Biovitrum AB and Takeda Pharmaceutical Co. Ltd. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavioa's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents
Product Code: IRTNTR41186

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type placement
  • Hemophilia A - Market size and forecast 2019-2024
  • Hemophilia B - Market size and forecast 2019-2024
  • Hemophilia C - Market size and forecast 2019-2024
  • Market opportunity by Type

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Bayer AG
  • CSL Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Grifols SA
  • Novo Nordisk AS
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Co. Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits:

  • 1. Key Finding 1
  • 2. Key Finding 2
  • 3. Key Finding 3
  • 4. Key Finding 4
  • 5. Key Finding 5
  • 6. Key Finding 6
  • 7. Key Finding 7
  • 8. Market in focus
  • 9. Parent market
  • 10. Market characteristics
  • 11. Product / Service portfolio of key vendors included in the market definition
  • 12. Market segments
  • 13. Global - Market size and forecast 2019 - 2024 ($ billion)
  • 14. Global market: Year-over-year growth 2019 - 2024 (%)
  • 15. Five forces analysis 2019 & 2024
  • 16. Bargaining power of buyers
  • 17. Bargaining power of suppliers
  • 18. Threat of new entrants
  • 19. Threat of substitutes
  • 20. Threat of rivalry
  • 21. Market condition - Five forces 2019
  • 22. Type placement - Market share 2019-2024 (%)
  • 23. Comparison by Type placement
  • 24. Hemophilia A - Market size and forecast 2019-2024 ($ billion)
  • 25. Hemophilia A - Year-over-year growth 2019-2024 (%)
  • 26. Hemophilia B - Market size and forecast 2019-2024 ($ billion)
  • 27. Hemophilia B - Year-over-year growth 2019-2024 (%)
  • 28. Hemophilia C - Market size and forecast 2019-2024 ($ billion)
  • 29. Hemophilia C - Year-over-year growth 2019-2024 (%)
  • 30. Market opportunity by Type
  • 31. Customer landscape
  • 32. Market share by geography 2019-2024 (%)
  • 33. Geographic comparison
  • 34. North America - Market size and forecast 2019-2024 ($ billion)
  • 35. North America - Year-over-year growth 2019-2024 (%)
  • 36. Europe - Market size and forecast 2019-2024 ($ billion)
  • 37. Europe - Year-over-year growth 2019-2024 (%)
  • 38. Asia - Market size and forecast 2019-2024 ($ billion)
  • 39. Asia - Year-over-year growth 2019-2024 (%)
  • 40. ROW - Market size and forecast 2019-2024 ($ billion)
  • 41. ROW - Year-over-year growth 2019-2024 (%)
  • 42. Key leading countries
  • 43. Market opportunity by geography ($ billion)
  • 44. Impact of drivers
  • 45. Impact of challenges
  • 46. Landscape disruption
  • 47. Industry risks
  • 48. Vendors covered
  • 49. Market positioning of vendors
  • 50. Bayer AG - Overview (1/3)
  • 51. Bayer AG - Overview (2/3)
  • 52. Bayer AG - Overview (3/3)
  • 53. Bayer AG - Business segments
  • 54. Bayer AG - Key offerings
  • 55. Bayer AG - Key customers
  • 56. Bayer AG - Segment focus
  • 57. CSL Ltd. - Overview (1/3)
  • 58. CSL Ltd. - Overview (2/3)
  • 59. CSL Ltd. - Overview (3/3)
  • 60. CSL Ltd. - Business segments
  • 61. CSL Ltd. - Key offerings
  • 62. CSL Ltd. - Key customers
  • 63. CSL Ltd. - Segment focus
  • 64. F. Hoffmann-La Roche Ltd. - Overview (1/3)
  • 65. F. Hoffmann-La Roche Ltd. - Overview (2/3)
  • 66. F. Hoffmann-La Roche Ltd. - Overview (3/3)
  • 67. F. Hoffmann-La Roche Ltd. - Business segments
  • 68. F. Hoffmann-La Roche Ltd. - Key offerings
  • 69. F. Hoffmann-La Roche Ltd. - Key customers
  • 70. F. Hoffmann-La Roche Ltd. - Segment focus
  • 71. Grifols SA - Overview (1/3)
  • 72. Grifols SA - Overview (2/3)
  • 73. Grifols SA - Overview (3/3)
  • 74. Grifols SA - Business segments
  • 75. Grifols SA - Key offerings
  • 76. Grifols SA - Key customers
  • 77. Grifols SA - Segment focus
  • 78. Novo Nordisk AS - Overview (1/3)
  • 79. Novo Nordisk AS - Overview (2/3)
  • 80. Novo Nordisk AS - Overview (3/3)
  • 81. Novo Nordisk AS - Business segments
  • 82. Novo Nordisk AS - Key offerings
  • 83. Novo Nordisk AS - Key customers
  • 84. Novo Nordisk AS - Segment focus
  • 85. Octapharma AG - Overview (1/3)
  • 86. Octapharma AG - Overview (2/3)
  • 87. Octapharma AG - Overview (3/3)
  • 88. Octapharma AG - Business segments
  • 89. Octapharma AG - Key offerings
  • 90. Octapharma AG - Key customers
  • 91. Octapharma AG - Segment focus
  • 92. Pfizer Inc. - Overview (1/3)
  • 93. Pfizer Inc. - Overview (2/3)
  • 94. Pfizer Inc. - Overview (3/3)
  • 95. Pfizer Inc. - Business segments
  • 96. Pfizer Inc. - Key offerings
  • 97. Pfizer Inc. - Key customers
  • 98. Pfizer Inc. - Segment focus
  • 99. Sanofi - Overview (1/3)
  • 100. Sanofi - Overview (2/3)
  • 101. Sanofi - Overview (3/3)
  • 102. Sanofi - Business segments
  • 103. Sanofi - Key offerings
  • 104. Sanofi - Key customers
  • 105. Sanofi - Segment focus
  • 106. Swedish Orphan Biovitrum AB - Overview (1/3)
  • 107. Swedish Orphan Biovitrum AB - Overview (2/3)
  • 108. Swedish Orphan Biovitrum AB - Overview (3/3)
  • 109. Swedish Orphan Biovitrum AB - Business segments
  • 110. Swedish Orphan Biovitrum AB - Key offerings
  • 111. Swedish Orphan Biovitrum AB - Key customers
  • 112. Swedish Orphan Biovitrum AB - Segment focus
  • 113. Takeda Pharmaceutical Co. Ltd. - Overview (1/3)
  • 114. Takeda Pharmaceutical Co. Ltd. - Overview (2/3)
  • 115. Takeda Pharmaceutical Co. Ltd. - Overview (3/3)
  • 116. Takeda Pharmaceutical Co. Ltd. - Business segments
  • 117. Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 118. Takeda Pharmaceutical Co. Ltd. - Key customers
  • 119. Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 120. Currency conversion rates for US$
  • 121. Research Methodology
  • 122. Validation techniques employed for market sizing
  • 123. Information sources
  • 124. List of abbreviations
Back to Top